Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

  1. Voss, M.H.
  2. Gordon, M.S.
  3. Mita, M.
  4. Rini, B.
  5. Makker, V.
  6. Macarulla, T.
  7. Smith, D.C.
  8. Cervantes, A.
  9. Puzanov, I.
  10. Pili, R.
  11. Wang, D.
  12. Jalal, S.
  13. Pant, S.
  14. Patel, M.R.
  15. Neuwirth, R.
  16. Enke, A.
  17. Shou, Y.
  18. Sedarati, F.
  19. Faller, D.V.
  20. Burris, H.A.
Revue:
British Journal of Cancer

ISSN: 1532-1827,  0007-0920

Année de publication: 2020

Volumen: 123

Número: 11

Pages: 1590-1598

Type: Article

DOI: 10.1038/S41416-020-01041-X GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus